The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...

Montelukast does not appear to increase the risk for neuropsychiatric adverse events in children and adolescents, according to a study published in JAMA Pediatrics. Montelukast is a leukotriene ...

Looking for ways to treat your gray hair? We talked to hair stylists and dermatologists to learn their secrets — and product ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

Women aged 18 to 45 years with IBD were invited to complete a survey regarding knowledge, attitude, and beliefs about contraception.

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S.

Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...